Non-opioid Pain Patch Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Non-opioid Pain Patch market is segmented by Patch Type (Lidocaine Patches, Diclofenac Patches, Capsaicin Patches, Ketoprofen Patches, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), and Geography Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The Report Offers the Value (in USD million) for the Above Segments.

Market Snapshot

Non-Opioid Pain Patch Market Summary
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 3.0 %
Non-Opioid Pain Patch Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Non-opioid Pain Patch market is expected to register a CAGR of 3.0% during the forecast period, 2022-2027.

The COVID-19 pandemic has impacted the healthcare systems across the world. The health agencies are engaged in containing coronavirus transmission through lockdown norms and have deferred most of the elective and non-urgent surgeries globally. According to the study titled "Pain Management during the COVID-19 Pandemic" published in Pain and Therapy in December 2020, opioid overuse, surgical overuse, and a failure to provide education or advice are examples of general, pre-existing problems that have been exacerbated as a result of the COVID-19 pandemic. As a result, the use of non-opioid pain relievers has increased. For COVID-19 patients, newly prescribed oral NSAIDs may only be used intermittently for a very short period. Thus, the Non-Opioid pain patch market significantly impacted COVID-19.

Pain has a deeper impact on the socio-economic system than the combination of cardiovascular diseases, cancer, and diabetes together. The global incidence of cancer is high. As per the GLOBOCAN 2020 report, the incidence of new cancer cases accounted for 19.3 globally and these cases are expected to increase and reach up to 30.2 million by 2040. Thus, the high incidence of cancer may increase the demand for cancer pain management drugs and devices, thereby boosting the market.

Similarly, cardiovascular disease (CVD) is one of the main causes of death among the adult population, globally. Chronic pain initiates in numerous ways, for instance, from trauma which could include an accident or back strain due to heavy lifting, an underlying disease like pancreatitis, spine disease, arthritis, or autoimmune diseases, or it can occur with fibromyalgia or persistent migraines. For instance, National Spinal Cord Injury Statistical Center (NSCISC) 2021 datasheet has accounted the annual incidence of spinal cord injuries at 60 cases per million. There are numerous risk factors for chronic pain. Non-opioid patches are preferable because it does not involve the risk of addiction as with opioid drug patches like fentanyl patches, and also the drugs are released over a long period, therefore, helping in managing the pain for a longer duration and considered a valuable driver for the Non-opioid Pain Patch market.

Meanwhile, a few other players are conducting extensive R&D by collaborating with educational institutions to introduce new non-narcotic pain patches. For Instance, in July 2020, The United States Food and Drug Administration approved an 8% capsaicin patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet in adults. The patch is a non-opioid, non-systemic, and topical pain treatment that is the only one on the market that delivers prescription-strength capsaicin directly into the patient's skin.

However, the availability of alternative treatments and the low adoption rate of non-opioid pain patch due to unawareness is expected to impede the growth of the non-opioid pain patch market.

Scope of the Report

As per the scope of the report, Non-opioids pain patches are primarily used for pain relief. These patches release their medicine content through the skin surface and block the pain signal transmission. The Non-opioid Pain Patch market is segmented by Patch Type (Lidocaine Patches, Diclofenac Patches, Capsaicin Patches, Ketoprofen Patches, and Others), Distribution Channel ( Hospital Pharmacies, Retail Pharmacies, Others), and Geography Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Patch Type
Lidocaine Patches
Diclofenac Patches
Capsaicin Patches
Ketoprofen Patches
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Lidocaine Patches Segment is Expected to Show Better Growth in the Forecast Years

Lidocaine patches are considered the most commonly available patch for the treatment of chronic and acute pain. The factors such as the rise in prevalence of pain and product launch by the key market players boost the segment growth.

Moreover, the data published in October 2021 by World Health Organization (WHO) reported that the pace of population aging is much faster than in the past and by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time, the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. The high incidence of chronic pain among Americans and the growing geriatric population are expected to increase the demand for pain management devices and drugs over the forecast period. Thus, rising chronic pain cases and the widespread availability of lidocaine pain relief patches are expected to drive the segment.

Increasing product launches by key market players are anticipated to boost the market. For instance, in August 2020, Amneal Pharmaceuticals, Inc. received Abbreviated New Drug Application (ANDA) approval from the United States Food and Drug Administration (FDA) for a generic version of Lidocaine Patch 5%. Lidocaine Patch, 5% is the generic version of Lidoderm Patch, 5% for the treatment of post-herpetic neuralgia.

Furthermore, the increasing burden of diseases, along with the safety profile and efficacy associated with lidocaine patches, are expected to drive the growth of the Non-opioid Pain Patch market during the forecast period.

Non-Opioid Pain Patch Market : Funding for the Pain Research (in Million), United States, 2019-2021

North America is Expected to Dominate the Non-opioid Pain Patch Market Over the Forecast Period

North America is expected to retain its dominance in this market due to the rising prevalence of pain in the region as well as product launches by the key market players in the region are expected to boost the market growth over the forecast period.

Chronic pain is one of the primary factors responsible for the growth of the market. According to the study titled " Prevalence of Pain Management Techniques Among Adults With Chronic Pain in the United States, 2019," published in the JAMA Network in February 2022, it is estimated that one in every five adults in the United States suffers from chronic pain. 1 in 14 adults experienced severe chronic pain. In addition, the countries in North America are increasingly facing scrutiny on the opioid crisis issue from the government authorities, which in turn are expected to benefit from the rise of non-opioid alternatives. Thus, the rising disease burden is further pushing the need for effective and quick treatment options, which is expected to propel the growth of the market over the forecast period.

In addition, product launches by the key market players are anticipated to boost the market over the forecast period. For instance, in July 2020, The United States Food and Drug Administration approved an 8% capsaicin patch (Qutenza, Grünenthal, and Averitas Pharma) for treating adults with neuropathic pain associated with diabetic peripheral neuropathy of the feet.

Thus, all aforementioned factors are anticipated to boost the market over the forecast period.

Non-Opioid Pain Patch Market : Growth Rate by Region

Competitive Landscape

The market is highly fragmented because numerous companies are working to help a large global population suffering from chronic pain. To increase consumer base and product penetration, various market players use a wide range of technologies to develop products that facilitate effective and prolonged drug release. Furthermore, the market is highly competitive, with fierce competition between existing players and new entrants. The global players in the non-opioid pain patch market are – Clarion Brands Inc., Endo Pharmaceuticals, Hisamitsu Pharmaceutical, Sanofi, Sorrento Therapeutics (SCILEX Pharmaceuticals), TEH SENG Pharmaceutical, Teikoku Seiyaku, Teva Pharmaceuticals, and Veridian Healthcare.

Major Players

  1. Endo Pharmaceuticals Inc.

  2. Hisamitsu Pharmaceutical Co. Inc.

  3. Teva Pharmaceuticals Industries Ltd.

  4. Veridian Healthcare

  5. Sanofi SA

Non-Opioid Pain Patch Market Concentration

Recent Development

  • In May 2022, Hisamitsu America Celebrates Salonpas Day with Free Patch Offer from Doctor Recommended OTC Pain Relief Patch Brand. Salonpas was named the number-one doctor-recommended brand of pain relief patches in the United States in 2021
  • In February 2022, NEXGEL, Inc., a provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, reported the launch of its MEDAGEL Bug Bite Relief Patch. These cooling patches, made in the USA using NEXGEL's soothing hydrogel technology, provide instant relief to irritated skin caused by insect bites.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Burden of Pain-Related Disorders

      2. 4.2.2 Rising R&D in Pain Management Treatments

      3. 4.2.3 Benefits Associated with Non-opioid Pain Patches Over Conventional Medications

    3. 4.3 Market Restraints

      1. 4.3.1 Availability of Alternative Treatments

      2. 4.3.2 Low Adoption Rate of Non-opioid Pain Patch due to Unawareness

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value – USD million)

    1. 5.1 By Patch Type

      1. 5.1.1 Lidocaine Patches

      2. 5.1.2 Diclofenac Patches

      3. 5.1.3 Capsaicin Patches

      4. 5.1.4 Ketoprofen Patches

      5. 5.1.5 Others

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

      3. 5.2.3 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Endo Pharmaceuticals Inc.

      2. 6.1.2 Hisamitsu Pharmaceutical Co. Inc.

      3. 6.1.3 Sanofi S.A.

      4. 6.1.4 Sorrento Therapeutics (SCILEX Pharmaceuticals)

      5. 6.1.5 TEH SENG Pharmaceutical Mfg Co

      6. 6.1.6 Teikoku Seiyaku Co. Ltd.

      7. 6.1.7 Teva Pharmaceuticals Industries Ltd.

      8. 6.1.8 Averitas Pharma

      9. 6.1.9 Grünenthal (Averitas Pharma)

      10. 6.1.10 Veridian Healthcare

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Non-opioid Pain Patch Market market is studied from 2019 - 2027.

The Global Non-opioid Pain Patch Market is growing at a CAGR of 3.0% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Endo Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Teva Pharmaceuticals Industries Ltd., Veridian Healthcare, Sanofi SA are the major companies operating in Global Non-opioid Pain Patch Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!